Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL)

Deutsche Bank AG boosted its stake in shares of Candel Therapeutics, Inc. (NASDAQ:CADL) by 5,814.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,522 shares of the company’s stock after buying an additional 30,989 shares during the period. Deutsche Bank AG owned 0.10% of Candel Therapeutics worth $274,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of CADL. Rhumbline Advisers lifted its holdings in Candel Therapeutics by 17.0% during the fourth quarter. Rhumbline Advisers now owns 26,272 shares of the company’s stock worth $228,000 after buying an additional 3,817 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in Candel Therapeutics during the fourth quarter worth $329,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Candel Therapeutics by 11.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 52,190 shares of the company’s stock valued at $453,000 after purchasing an additional 5,413 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in shares of Candel Therapeutics during the 4th quarter valued at $357,000. Finally, Halter Ferguson Financial Inc. lifted its holdings in shares of Candel Therapeutics by 123.7% during the 4th quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company’s stock valued at $5,914,000 after purchasing an additional 376,795 shares during the last quarter. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CADL. Bank of America began coverage on Candel Therapeutics in a report on Friday, February 7th. They set a “buy” rating and a $15.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $19.00 target price on shares of Candel Therapeutics in a research report on Friday, April 11th. Canaccord Genuity Group upped their target price on Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th. Citigroup assumed coverage on Candel Therapeutics in a research report on Thursday, February 20th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Wall Street Zen raised Candel Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Candel Therapeutics Price Performance

NASDAQ CADL opened at $5.53 on Monday. The stock’s fifty day moving average price is $5.19 and its 200 day moving average price is $6.73. Candel Therapeutics, Inc. has a 1 year low of $3.79 and a 1 year high of $14.60. The company has a market cap of $277.07 million, a price-to-earnings ratio of -3.20 and a beta of -0.92.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.37. Research analysts expect that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current year.

Insiders Place Their Bets

In other Candel Therapeutics news, insider Charles Schoch sold 5,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.83, for a total transaction of $44,150.00. Following the sale, the insider now directly owns 38,038 shares of the company’s stock, valued at approximately $335,875.54. This trade represents a 11.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Seshu Tyagarajan sold 31,278 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $8.82, for a total value of $275,871.96. Following the sale, the chief technology officer now directly owns 85,512 shares in the company, valued at $754,215.84. This represents a 26.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. 16.60% of the stock is owned by insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.